This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Diaz, R. M. Articles by Vile, R. G. Search for Related Content PubMed PubMed Citation Articles by Diaz, R. M. Articles by Vile, R. G.

Oncolytic Immunovirotherapy for Melanoma Using Vesicular Stomatitis Virus

¹ Molecular Medicine Program and ² Department of Immunology, Mayo Clinic, Rochester, Minnesota; ³ Department of Microbiology and Immunology, Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, Florida; and ⁴ Cancer Research UK Clinical Centre, St. James's University Hospital, Leeds, United Kingdom

Requests for reprints: Richard G. Vile, Molecular Medicine Program, Guggenheim 1836, Mayo Clinic, 200 1st Street Southwest, Rochester, MN 55905. Phone: 507-284-9941; Fax: 507-266-2122; E-mail: vile.richard{at}mayo.edu.

Relatively little attention has been paid to the role of virotherapy in promoting antitumor immune responses. Here, we show that CD8+ T cells are critical for the efficacy of intratumoral vesicular stomatitis virus virotherapy and are induced against both virally encoded and tumor-associated immunodominant epitopes. We tested three separate immune interventions to increase the frequency/activity of activated antitumoral T cells. Depletion of Treg had a negative therapeutic effect because it relieved suppression of the antiviral immune response, leading to early viral clearance. In contrast, increasing the circulating levels of tumor antigen–specific T cells using adoptive T cell transfer therapy, in combination with intratumoral virotherapy, generated significantly improved therapy over either adoptive therapy or virotherapy alone. Moreover, the incorporation of a tumor-associated antigen within the oncolytic vesicular stomatitis virus increased the levels of activation of naïve T cells against the antigen, which translated into increased antitumor therapy. Therefore, our results show that strategies which enhance immune activation against tumor-associated antigens can also be used to enhance the efficacy of virotherapy. [Cancer Res 2007;67(6):2840–7]

This article has been cited by other articles:

				R. J. Prestwich, F. Errington, E. J. Ilett, R. S.M. Morgan, K. J. Scott, T. Kottke, J. Thompson, E. E. Morrison, K. J. Harrington, H. S. Pandha, et al. Tumor Infection by Oncolytic Reovirus Primes Adaptive Antitumor Immunity Clin. Cancer Res., November 15, 2008; 14(22): 7358 - 7366. [Abstract] [Full Text] [PDF]

				A. Gauvrit, S. Brandler, C. Sapede-Peroz, N. Boisgerault, F. Tangy, and M. Gregoire Measles Virus Induces Oncolysis of Mesothelioma Cells and Allows Dendritic Cells to Cross-Prime Tumor-Specific CD8 Response Cancer Res., June 15, 2008; 68(12): 4882 - 4892. [Abstract] [Full Text] [PDF]

				F. Errington, L. Steele, R. Prestwich, K. J. Harrington, H. S. Pandha, L. Vidal, J. de Bono, P. Selby, M. Coffey, R. Vile, et al. Reovirus Activates Human Dendritic Cells to Promote Innate Antitumor Immunity J. Immunol., May 1, 2008; 180(9): 6018 - 6026. [Abstract] [Full Text] [PDF]